Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05908253 · ClinicalTrials.gov registry record · NA
Toward a Generalizable Closed-loop Neurofeedback-based BCI for Attention Training
A NA study of Neurofeedback, sponsored by University of Rhode Island.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT05908253: Completed NA study of Neurofeedback, sponsored by University of Rhode Island.
NCT05908253 is a NA study of Neurofeedback that has completed, run by University of Rhode Island. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05908253, a NA study of Neurofeedback, has completed, sponsored by University of Rhode Island.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study accelerates the translational aspect of neurofeedback-based attention training using novel technologies, algorithms, and neuromarkers. The presented brain training intervention and approaches will not only be applicable to attention remedy in patients with attention deficits but also can be applied to treatment of other neurocognitive (mental) disorders such as anxiety, depression, and addiction.
Primary Outcome
This outcome focuses on the effectiveness of closed-loop algorithms for neurofeedback-based attention training. The behavioral responses to instructed stimuli before and after closed-loop neurofeedback will be measured by push buttons and will be evaluated.
Conditions Studied
Interventions
- BEHAVIORAL sham neurofeedback
- BEHAVIORAL nonadaptive neurofeedback
- BEHAVIORAL adaptive neurofeedback
Study Locations (1)
Rhode Island
- University of Rhode Island - Kingston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-12-16 |
| Est. Completion | 2024-04-30 |
| Phase | NA |
What the finished NCT05908253 record still lists
NCT05908253 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Neurofeedback appearing as the primary indexed condition, and to 3 interventions - of which sham neurofeedback is the first listed.
NCT05908253 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT05908253 about?
NCT05908253 is a clinical study titled "Toward a Generalizable Closed-loop Neurofeedback-based BCI for Attention Training". The proposed study accelerates the translational aspect of neurofeedback-based attention training using novel technologies, algorithms, and neuromarkers. The presented brain training intervention and approaches will not only be applicable to attention remedy in patients with attention deficits but a...
What is the current status of trial NCT05908253?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2023-12-16. Estimated completion is 2024-04-30.
What conditions does trial NCT05908253 study?
This clinical trial studies the following conditions: Neurofeedback.
What interventions are being tested in trial NCT05908253?
The interventions under investigation include: sham neurofeedback (BEHAVIORAL), nonadaptive neurofeedback (BEHAVIORAL), adaptive neurofeedback (BEHAVIORAL).
Who is sponsoring clinical trial NCT05908253?
This trial is sponsored by University of Rhode Island, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05908253 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofeedback
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05908253's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI